RAG 18
Alternative Names: RAG-18Latest Information Update: 10 Nov 2023
At a glance
- Originator Ractigen Therapeutics
- Class Oligonucleotides; RNA
- Mechanism of Action Gene expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Duchenne muscular dystrophy
Most Recent Events
- 02 Nov 2023 Preclinical trials in Duchenne muscular dystrophy in China (Parenteral)
- 02 Nov 2023 Pharmacodynamics data from preclinical trial in Duchenne muscular dystrophy released by Ractigen Therapeutics
- 02 Nov 2023 Ractigen Therapeutics plans to initiate a phase I trial for Duchenne muscular dystrophy (Parenteral), by early 2025